Arcturus Therapeutics Holdings Inc. cash flow to debt ratio of -297.11% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Arcturus Therapeutics Holdings Inc.'s free cash flow has decreased 22.98% from $-60.40M last year to $-74.27M, signaling decreasing performance

Arcturus Therapeutics Holdings Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

Arcturus Therapeutics Holdings Inc.'s debt has increased relative to shareholder equity from 0.12 last year to 0.13 today, signaling weakened financials

Arcturus Therapeutics Holdings Inc. has a net cash position, so leverage is healthy.

Arcturus Therapeutics Holdings Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Arcturus Therapeutics Holdings Inc.'s profit margin has decreased (570.05%) in the last year from -58.49% to -391.90%, signaling decreasing performance

Arcturus Therapeutics Holdings Inc.'s short-term assets of $241.45M exceed its short-term liabilities of $36.38M

Arcturus Therapeutics Holdings Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arcturus Therapeutics Holdings Inc.'s return on equity of -46.54%, is lower than 15.00%, indicating bad performance

Arcturus Therapeutics Holdings Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arcturus Therapeutics Holdings Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Arcturus Therapeutics Holdings Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Arcturus Therapeutics Holdings Inc. has negative free cash flow, indicating cash burn

Arcturus Therapeutics Holdings Inc.'s yearly earnings has increased -18.73% since last year from $-80.94M to $-65.78M, signaling increasing performance

Arcturus Therapeutics Holdings Inc.'s yearly revenue has decreased 40.72% since last year from $138.39M to $82.03M, signaling decreasing performance

ROIC -52.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Arcturus Therapeutics Holdings Inc.'s 3-year revenue CAGR of -31.13% is negative, indicating declining revenue over the past 3 years

Arcturus Therapeutics Holdings Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Arcturus Therapeutics Holdings Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Arcturus Therapeutics Holdings Inc. has insufficient data to evaluate this check.

Arcturus Therapeutics Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcturus Therapeutics Holdings Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Arcturus Therapeutics Holdings Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Arcturus Therapeutics Holdings Inc. is overvalued relative to its fair value price of -32.84 based on Earnings Fair Value model

Arcturus Therapeutics Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcturus Therapeutics Holdings Inc. has a price-to-book ratio of 1.17x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Arcturus Therapeutics Holdings Inc. has a price-to-sales ratio of 8.42x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue